Kare Schultz Sells Shares of Hims & Hers Health

On June 11, 2026, Kare Schultz sold 3,656 shares of Hims & Hers Health, Inc. (NYSE:HIMS). The transaction was not planned and did not disclose a sale price. As of now, the stock is trading at $26.82.

Insider Buying and Selling at Hims & Hers Health, Inc.

Kare Schultz's transaction on June 11 is part of a series of insider activities at Hims & Hers Health. Other insiders, including Christopher Payne and Anja Manuel, also made transactions on June 15. Payne sold 10,687 shares while Manuel sold 10,040 shares. David Wells sold 957 shares and simultaneously bought the same number, indicating a possible strategy to balance holdings.

Other Institutional Activity in Hims & Hers Health

Several institutional investors have been active in Hims & Hers Health. BlackRock, Inc. reduced its holdings by 236,346 shares, ending with 26,337,158 shares valued at approximately $547 million. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both established new positions, each holding over 9 million shares valued at about $211 million and $194 million, respectively. Morgan Stanley significantly increased its stake by adding 4,959,856 shares, reaching a total of 8,889,088 shares worth $185 million. State Street Corp also added 154,498 shares, bringing its total to 7,460,023 shares valued at $155 million.

Hims & Hers Health Stock Snapshot

Shares of Hims & Hers Health (NYSE:HIMS) are trading near $26.82. The company has a market cap of approximately $6.21 billion and a forward P/E ratio of 30.13. With a beta of 2.398, the stock has seen a 52-week low of $13.74 and a high of $70.43. It has a 50-day moving average of $25.63 and a 200-day moving average of $33.57. The company's current ratio stands at 1.689, and its quick ratio is 1.455, with a debt-to-equity ratio of 253.725.

Recent Earnings

In its latest earnings report, Hims & Hers Health posted revenue of $2.37 billion, reflecting a growth rate of 3.8%. However, the company reported a net margin of -0.56% and a return on equity of -2.66%. The next earnings report is expected on August 10, 2026.

Analysts Set New Price Targets

Analysts have mixed views on Hims & Hers Health. On May 26, 2026, B of A Securities maintained its hold rating with a $25.00 price target. Truist Securities followed on May 22 with the same rating and a $23.00 target. JP Morgan and Needham are more bullish, maintaining buy ratings with price targets of $33.00 and $35.00, respectively. The overall analyst consensus is a hold, with a mean price target of $26.61 based on 14 analyst opinions.

About Hims & Hers Health

Hims & Hers Health, Inc. is a healthcare company based in San Francisco, California. It operates a digital health platform that connects consumers with licensed healthcare professionals. The company offers a range of health and wellness products, including prescription and non-prescription items, focusing on areas like skincare, sexual health, and hair care. Under the leadership of CEO Andrew Dudum, Hims & Hers also provides medical consultations and lab testing services across several countries, including the U.S., U.K., and Canada.

Bottom Line

Kare Schultz's recent sale of Hims & Hers Health shares highlights ongoing insider activity at the company. Investors keep a close eye on such transactions to gauge insider sentiment. While the stock trades near $26.82, analysts have a hold consensus with a mean price target of $26.61. Remember, insider trades are disclosed after the fact and may not reflect current positions.